Actinium Pharmaceuticals (ATNM)
(Delayed Data from AMEX)
$1.60 USD
-0.02 (-1.23%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ATNM 1.60 -0.02(-1.23%)
Will ATNM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ATNM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATNM
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates
ATNM: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy
Other News for ATNM
Actinium Pharmaceuticals (ATNM) Showcases Promising Prostate Cancer Treatment Data
Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer ...
Actinium Pharmaceuticals' ATNM-400 shows improved survival in prostate cancer
Promising Preclinical Results for ATNM-400 Drive Buy Rating for Actinium Pharmaceuticals
Actinium Pharma (ATNM) Rating Reaffirmed with Stable Price Target | ATNM Stock News